Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 8/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | NT5E | P21589 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.39 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | RAF1 | P04049 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6185563 | 0.91 | MAPK14 (0.43) | MAPK14GAANT5ECSNK1DCSNK1E | |
| SCHEMBL6184293 | 0.90 | NT5E (0.41) | MAPK14NT5ETP53MEN1KMT2A | |
| SCHEMBL6182069 | 0.90 | NT5E (0.41) | MAPK14NT5ETP53CSNK1DCSNK1E | |
| SCHEMBL6183056 | 0.89 | MAPK14 (0.43) | MAPK14NT5ECSNK1DCSNK1EPDE10A | |
| SCHEMBL6183189 | 0.83 | MAPK14 (0.40) | MAPK14GAANT5ETP53CSNK1D | |
| SCHEMBL6186115 | 0.80 | NT5E (0.42) | MAPK14GAANT5ETP53MAPT | |
| SCHEMBL6184613 | 0.80 | KCNMA1 (0.43) | MAPK14NT5EMEN1KMT2A | |
| SCHEMBL6186458 | 0.80 | NT5E (0.43) | MAPK14GAANT5ERAF1 | |
| SCHEMBL6184681 | 0.78 | NT5E (0.42) | MAPK14GAANT5ERAF1 | |
| SCHEMBL6182974 | 0.77 | MAPK14 (0.41) | MAPK14CSNK1DCSNK1EPDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1247810-B1 | Novel benzotriazoles anti-inflammatory compounds | PFIZER PROD INC (US) | 2005-09-07 | — | — | EP | disclosed |
| US-6664395-B2 | Benzotriazole compoundsn are the potent inhibitors of MAP kinases, preferably p38 kinase. They are useful for treating inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion, ischemia | PFIZER INC | 2003-12-16 | — | — | US | disclosed |
| US-20030078432-A1 | Novel benzotriazoles anti-inflammatory compounds | PFIZER INC. | 2003-04-24 | — | — | US | disclosed |
| EP-1247810-A1 | Novel benzotriazoles anti-inflammatory compounds | Pfizer Products Inc. (US) | 2002-10-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078432-A1 | Novel benzotriazoles anti-inflammatory compounds | MAPK1, JAK1, RUNX1 | MAPK14 27/4885GAA 4762/4885NT5E 4156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.